Showing 2756 results
-
Press release /China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis Moderate-to-severe plaque…
-
Press release /Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
-
Press release /Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21…
-
Ad hoc release /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs im zweiten Quartal um +9% (kWk¹, +14% USD): Die Geschäftseinheit Pharmaceuticals legte +12% (kWk, +18% USD) zu mit…
-
Press release /ALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
-
Press release /Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (…
-
Press release /At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia New…